Vitae Pharmaceuticals, Inc. Reports Positive Clinical Data in Chronic Kidney Disease Program at the American Diabetes Association's 71st Scientific Sessions
Published: Jun 27, 2011
FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Vitae Pharmaceuticals today announced results of a Phase I clinical study in healthy volunteers demonstrating the Company’s lead compound, VTP-27999, significantly reduced the activity of the renin-angiotensin-aldosterone system (RAAS) in the kidney. The RAAS pathway is considered to have a central role in the progression of chronic kidney disease, particularly in diabetes, and diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). The clinical findings were presented in a poster presentation titled, “VTP-27999: A Novel Direct Renin Inhibitor with Potential for Superior Renal Protection in Diabetic Nephropathy”, at the 71st Scientific Sessions of the American Diabetes Association being held in San Diego, California, from June 24 to 28.